XML 100 R119.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment and Geographical Data (Schedule of Segment Reporting Information by Business Segment) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 12 Months Ended
Sep. 27, 2013
Jun. 28, 2013
Mar. 29, 2013
Dec. 28, 2012
Sep. 28, 2012
Jun. 29, 2012
Mar. 30, 2012
Dec. 30, 2011
Sep. 27, 2013
Sep. 28, 2012
Sep. 30, 2011
Segment Reporting Information [Line Items]                      
Net sales $ 545.2 $ 570.0 [1] $ 585.3 $ 504.0 $ 513.1 $ 516.3 $ 523.1 $ 503.7 $ 2,204.5 $ 2,056.2 $ 2,021.8
Operating income (loss)                 144.8 235.2 240.7
Intangible asset amortization                 (35.4) (27.3) (27.0)
Restructuring and related charges, net                 (35.8) (19.2) (10.0)
Separation costs                 (74.2) (25.5) (2.9)
Assets 3,556.6       2,898.9       3,556.6 2,898.9  
Depreciation and amortization                 139.6 130.9 119.8
Restructuring and related costs, accelerated depreciation                 2.6 8.0 1.6
Specialty Pharmaceuticals
                     
Segment Reporting Information [Line Items]                      
Restructuring and related charges, net                 (16.4) (11.3) (6.5)
Global Medical Imaging
                     
Segment Reporting Information [Line Items]                      
Restructuring and related charges, net                 (16.4) (7.9) (3.8)
Operating Segments
                     
Segment Reporting Information [Line Items]                      
Net sales                 2,153.3 [2] 2,002.0 [2] 1,969.4 [2]
Operating income (loss)                 424.0 377.1 353.9
Operating Segments | Specialty Pharmaceuticals
                     
Segment Reporting Information [Line Items]                      
Net sales                 1,217.6 1,005.2 909.4
Operating income (loss)                 311.7 162.8 121.5
Assets 1,666.6       1,571.6       1,666.6 1,571.6  
Depreciation and amortization                 97.6 [3] 88.7 [3] 77.5 [3]
Operating Segments | Global Medical Imaging
                     
Segment Reporting Information [Line Items]                      
Net sales                 935.7 996.8 1,060.0
Operating income (loss)                 112.3 214.3 232.4
Assets 1,158.6       1,085.7       1,158.6 1,085.7  
Depreciation and amortization                 42.0 42.2 42.3
Corporate, Non-Segment
                     
Segment Reporting Information [Line Items]                      
Net sales                 51.2 [4] 54.2 [4] 52.4 [4]
Corporate and allocated expenses                 (133.8) [5] (69.9) [5] (73.3) [5]
Intangible asset amortization                 (35.4) (27.3) (27.0)
Restructuring and related charges, net                 (35.8) [6] (19.2) [6] (10.0) [6]
Separation costs                 (74.2) (25.5) (2.9)
Assets 731.4 [7]       241.6 [7]       731.4 [7] 241.6 [7]  
Intersegment Eliminations
                     
Segment Reporting Information [Line Items]                      
Net sales                 $ 0 $ 0 $ 0
[1] Operations in the third quarter of fiscal 2013 were impacted by the Separation.
[2] Amounts represent sales to external customers. There were no intersegment sales.
[3] Depreciation for certain shared facilities is allocated based on occupancy percentage.
[4] Represents products that were sold to Covidien, which is discussed in Note 16.
[5] Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
[6] Includes restructuring-related accelerated depreciation of $2.6 million, $8.0 million and $1.6 million for fiscal 2013, 2012 and 2011, respectively.
[7] Consists of assets used in managing the Company's total business and not allocated to any one segment.